Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/ Refractory B-ALL

被引：1
|
作者：
Gauthier, Jordan [1 ,2 ]
Gazeau, Nicolas [3 ]
Fiorenza, Salvatore [4 ]
Kimble, Erik L. [4 ,5 ]
Hirayama, Alexandre Vinaud [1 ,6 ]
Pender, Barbara S. [4 ]
Di, Henna N. [3 ]
Kirchmeier, Delaney R. [4 ]
Shadman, Mazyar [4 ,7 ]
Cassaday, Ryan D. [3 ,5 ]
Riddell, Stanley R. [2 ,4 ]
Maloney, David G. [2 ,3 ]
Turtle, Cameron J. [4 ,8 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[3] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA
[4] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA
[5] Univ Washington, Dept Med, Div Hematol, Seattle, WA USA
[6] Univ Washington, Dept Med Oncol, Seattle, WA USA
[7] Univ Washington, Div Hematol & Med Oncol, Seattle, WA USA
[8] Univ Washington, Dept Med, Seattle, WA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-156822
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10360 / 10362
页数：3
相关论文
共 50 条
  • [21] Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Geyer, Mark B.
    Riviere, Isabelle
    Senechal, Brigitte
    Wang, Xiuyan
    Wang, Yongzeng
    Purdon, Terence J.
    Hsu, Meier
    Devlin, Sean M.
    Palomba, M. Lia
    Halton, Elizabeth
    Bernal, Yvette
    van Leeuwen, Dayenne G.
    Sadelain, Michel
    Park, Jae H.
    Brentjens, Renier J.
    JCI INSIGHT, 2019, 4 (09)
  • [22] Successful Anti-CD 19 CAR-T Cell Therapy in Jehovah Witness Patient with Relapsed Refractory B-ALL
    Leal, Jordan
    Rodriguez, Liza
    Kus, Crissy
    Appenfeller, Allison
    Ganguly, Siddhartha
    McGuirk, Joseph P.
    Abhyankar, Sunil
    Singh, Anurag
    Lin, Tara
    Shune, Leyla
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S379 - S379
  • [23] CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY
    Zhang, Mingming
    Hu, Yongxian
    Lu, Peihua
    Huang, Liang
    Fu, Shan
    Feng, Jingjing
    Hong, Ruimin
    Chang, Alex H.
    Huang, He
    BONE MARROW TRANSPLANTATION, 2024, 59 : 146 - 146
  • [24] Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
    Aldoss, Ibrahim
    Khaled, Samer K.
    Wang, Xiuli
    Palmer, Joycelynne
    Wang, Yan
    Wagner, Jamie R.
    Clark, Mary C.
    Simpson, Jennifer
    Paul, Jinny
    Vyas, Vibhuti
    Chien, Sheng-Hsuan
    Stein, Anthony
    Pullarkat, Vinod
    Salhotra, Amandeep
    Al Malki, Monzr M.
    Aribi, Ahmed
    Sandhu, Karamjeet
    Thomas, Sandra H.
    Budde, Lihua E.
    Marcucci, Guido
    Brown, Christine E.
    Forman, Stephen J.
    CLINICAL CANCER RESEARCH, 2023, 29 (04) : 742 - 753
  • [25] Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Zhang, Xian
    Yang, Junfang
    Shi, Yanze
    Song, Dan
    Li, Jingjing
    Lu, Xin-an
    Wu, Fei
    Li, Jianqiang
    Chen, Dandan
    Li, Xiangqun
    Xu, Zhongwei
    Liu, Shuqiang
    Li, Ziyu
    Ying, Kui
    Wang, Wenya
    Lu, Peihua
    BLOOD, 2019, 134
  • [26] Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Li, Chunrui
    Wang, Jue
    Wang, Di
    Hu, Guang
    Yang, Yongkun
    Zhou, Xiaoxi
    Meng, Li
    Hong, Zhenya
    Chen, Liting
    Mao, Xia
    Xiao, Min
    Zhou, Jianfeng
    BLOOD, 2019, 134
  • [27] CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
    Myers, Regina M.
    DiNofia, Amanda M.
    Li, Yimei
    Diorio, Caroline
    Aplenc, Richard
    Baniewicz, Diane
    Brogdon, Jennifer L.
    Callahan, Colleen
    Engels, Boris
    Fraietta, Joseph A.
    Gonzalez, Vanessa
    Iannone, Emma
    Leahy, Allison Barz
    Liu, Hongyan
    McClory, Susan E.
    Rheingold, Susan R.
    Shinehouse, Laura
    Wertheim, Gerald
    Wray, Lisa
    Frey, Noelle, V
    Maude, Shannon L.
    Grupp, Stephan A.
    BLOOD, 2022, 140 : 2376 - 2377
  • [28] Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies
    Wang, Na
    Hu, Xuelian
    Cao, Wenyue
    Li, Chunrui
    Xiao, Yi
    Cao, Yang
    Gu, Chaojiang
    Zhang, Shangkun
    Chen, Liting
    Cheng, Jiali
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Zheng, Miao
    Mao, Xia
    Jiang, Lijun
    Wang, Di
    Wang, Qiuxiang
    Lou, Yaoyao
    Cai, Haodong
    Yan, Dandan
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    Huang, Liang
    BLOOD, 2020, 135 (01) : 17 - 27
  • [29] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
  • [30] Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy
    Ababneh, Hazim S.
    Frigault, Matthew J.
    Patel, Chirayu G.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
12345